Drug interactions with the newer antiepileptic drugs (AEDs) - Part 2: Pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders

Clinical Pharmacokinetics

Volumn 52, Issue 12, 2013, Pages 1045-1061

  Patsalos, Philip N ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM MAGNESIUM HYDROXIDE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ATORVASTATIN; CARDIAC AGENT; CIMETIDINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIGOXIN; ESLICARBAZEPINE ACETATE; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETIRACETAM; FANATREX; FELBAMATE; GABAPENTIN; GABARONE; HARKOSERIDE; LAMOTRIGINE; LIVER ENZYME; MESTRANOL PLUS NORETHISTERONE; METFORMIN; MICROGINON; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PERAMPANEL; PORTIGA; PREGABALIN; PSYCHOTROPIC AGENT; RETIGABINE; RISIDON; RUFINAMIDE; SIMVASTATIN; STIRIPENTOL; TIAGABINE; TOPIRAMATE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIGABATRIN; WARFARIN; ZONISAMIDE;

APLASTIC ANEMIA; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE;

ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY; HUMANS; PHARMACOKINETICS;

EID: 84890527382     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0088-z     Document Type: Review

References (69)

1. Patsalos PN, Bourgeois BF. The epilepsy prescriber's guide to antiepileptic drugs. New York: Cambridge University Press; 2010.
2. Johannessen LC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27-47.
3. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-85.
4. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs) - part 1. Pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. doi: 10.1007/s40262-013-0087-0.
5. da Vaz SM, Costa R, Soares E, Maia J, Falcao A, Almeida L, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol. 2009;23:509-14.
6. Rocha JF, Vaz-da-Silva M, Almeida L, Falcao A, Nunes T, Santos AT, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther. 2009;47:255-61.
7. Falcao A, Vaz-da-Silva M, Gama H, Nunes T, Almeida L, Soares-da-Silva P. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res. 2013 Apr 6. pii: S0920-1211(13)00080-6. doi: 10.1016/j.eplepsyres.2013.02. 020. [Epub ahead of print].
8. Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53:935-46.
9. Vaz-da-Silva M, Almeida L, Falcao A, Soares E, Maia J, Nunes T, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther. 2010;32:179-92.
10. Saano V, Glue P, Banfield CR, Reidenberg P, Colucci RD, Meehan JW, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther. 1995;58:523-31.
11. Tisdel KA, Israel DS, Kolb KW. Warfarin-felbamate interaction: first report. Ann Pharmacother. 1994;28:805.
12. Busch JA, Radulovic LL, Bockbrader HN, Underwood BA, Sedman AJ, Chang T. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects [abstract]. Pharm Res. 1992;9(Suppl 2):S315.
13. Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69:498-507.
14. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A. Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006;2:981-1007.
15. Feng MR, Ouellet D, Li W, Berna K, Ferreira S, Knowlton P, et al. Pharmacokinetic interaction of gabapentin and naproxen in rats and humans [abstract]. Clin Pharmacol Ther. 2003;73:P50.
16. Depot M, Powell JR, Messenheimer JA Jr, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther. 1990;48:346-55.
17. Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2000;56:299-304.
18. Haan GJ, Efelbroek P, Bartels C. Changes in lamotrigine pharmacokinetics induced by antitubercular drugs [abstract]. Epilepsia. 2010;51(Suppl 4):26.
19. Schieber FC, Boulton DW, Balch AH, Croop R, Mallikaarjun S, Benson J, et al. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Hum Psychopharmacol. 2009;24:145-52.
20. Burger DM, Huisman A, Van EN, Neisingh H, Van UP, Rongen GA, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008;84:698-703.
21. Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25:342-8.
22. Bergemann N, Frick A, Parzer P, Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37:63-8.
23. Harden CL, Herzog AG, Nikolov BG, Koppel BS, Christos PJ, Fowler K, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47:1447-51.
24. van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80:159-68.
25. Sidhu J, Job S, Bullman J, Francis E, Abbott R, Ascher J, et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol. 2006;61:420-6.
26. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47:151-4.
27. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570-1.
28. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005;46:1414-7.
29. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol. 2006;61:191-9.
30. Contin M, Albani F, Ambrosetto G, Avoni P, Bisulli F, Riva R, et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia. 2006;47:1573-5.
31. Tomson T, Luef G, Sabers A, Pittschieler S, Ohman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology. 2006;67:1297-9.
32. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res. 2003;57:85-93.
33. Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res. 2000;42:23-31.
34. Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48:484-9.
35. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure. 2008;17:199-202.
36. Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat. Epilepsia. 2006;47:2207.
37. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure. 1998;7:163-5.
38. Waade RB, Christensen H, Rudberg I, Refsum H, Hermann M. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31:233-8.
39. Bullman J, Nicholls A, Van LK, Fleck R, Vuong A, Miller J, et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia. 2011;52:1351-8.
40. Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol. 2000;50:193-5.
41. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol. 2002;17:233-8.
42. Spina E, D'Arrigo C, Migliardi G, Santoro V, Muscatello MR, Mico U, et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit. 2006;28:599-602.
43. Andersson ML, Bjorkhem-Bergman L, Lindh JD. Possible drug-drug interaction between quetiapine and lamotrigine-evidence from a Swedish TDM database. Br J Clin Pharmacol. 2011;72:153-6.
44. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77-85.
45. Kramer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers [abstract]. Epilepsia. 1991;32(Suppl 1):70-1.
46. Pisani F, Fazio A, Oteri G, Artesi C, Xiao B, Perucca E, et al. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand. 1994;90:130-2.
47. Rosche J, Froscher W, Abendroth D, Liebel J. Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study. Clin Neuropharmacol. 2001;24:113-6.
48. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit. 1993;15:39-42.
49. van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol. 2003;14:1732-4.
50. Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol. 2008;3:198-203.
51. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40:783-7.
52. Angelopoulos P, Markopoulou M, Kyamidis K, Bobotas K. Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride. Gen Hosp Psychiatry. 2008;30:482-4.
53. Perampanel (Fycompa). Summary of product characteristics. Eisai Europe Ltd.; 2012.
54. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13-8.
55. Crean CS, Tompson DJ. The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine). Clin Ther. 2013;35:87-93.
56. Bodd E, Gadeholt G, Christensson PI, Morland J. Mechanisms behind the inhibitory effect of ethanol on the conjugation of morphine in rat hepatocytes. J Pharmacol Exp Ther. 1986;239:887-90.
57. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123-41.
58. Mengel HB, Jansen JA, Sommerville KW, Jonkman J, Wesnes K, Cohen A, et al. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol [abstract]. Epilepsia. 1995;36(Suppl 3):S160.
59. Burstein AH, Boudreau EA, Theodore WH. Increase in tiagabine serum concentration with coadministration of gemfibrozil. Ann Pharmacother. 2009;43:379-82.
60. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43:763-80.
61. Topamax (Topiramate). Summary of product characteristics. Janssen-Cilag Ltd.; 2012.
62. Marriott D, Levy R, Doyle T, Ray J. Posaconazole-induced topiramate toxicity. Ann Intern Med. 2009;151:143.
63. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21:645-53.
64. Doose DR, Kohl D, Desai-Krieger D, Natarajan J, van Kemmen DP. No clinically significant effect of topiramate on haloperidol plasma concentration [abstract]. Eur Neuropsychopharmacol. 1999;9(Suppl 4):S357.
65. Abraham G, Owen J. Topiramate can cause lithium toxicity. J Clin Psychopharmacol. 2004;24:565-7.
66. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317-23.
67. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540-9.
68. Okumura J. Decrease in plasma zonisamide concentrations after coadministration of risperidone in a patient with schizophrenia receiving zonisamide therapy [abstract]. Int Clin Psychopharmacol. 1999;14(1):55.
69. Patsalos PN. Antiepileptic drug interactions - a clinical guide. New York: Springer; 2013.